Synthesis, characterization and in vitro evaluation of a bone targeting delivery system for salmon Calcitonin

International Journal of Pharmaceutics

Volumn 394, Issue 1-2, 2010, Pages 26-34

  Bhandari, Krishna Hari ^a   Newa, Madhuri ^a   Uludag, Hasan ^a   Doschak, Michael R ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Bisphosphonate; Bone cancer; Bone targeting; Calcitonin; Drug delivery system; Osteoarthritis; Osteoporosis; Paget's disease; Rheumatoid arthritis

Indexed keywords

AGENTS AFFECTING METABOLISM; BIPHOSPHONATE SALCATONIN CONJUGATE; TRIETHYLAMINE; UNCLASSIFIED DRUG; BONE DENSITY CONSERVATION AGENT; CALCITONIN; ETHYLAMINE; MALEIMIDE DERIVATIVE; N,N DIMETHYLFORMAMIDE; SALCATONIN; SULFOSUCCINIMIDYL 4-(N-MALEIMIDOMETHYL)CYCLOHEXANE-1-CARBOXYLATE;

ARTICLE; BINDING AFFINITY; BONE MINERAL; BREAST CANCER; CANCER CELL; CELL STIMULATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG ACTIVITY; DRUG BINDING; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; FEASIBILITY STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; REACTION TIME; BONE; BONE DENSITY; BREAST TUMOR; CHEMISTRY; DRUG EFFECTS; MASS SPECTROMETRY; METABOLISM; TUMOR CELL LINE;

BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BREAST NEOPLASMS; CALCITONIN; CELL LINE, TUMOR; DIMETHYLFORMAMIDE; DRUG DELIVERY SYSTEMS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ETHYLAMINES; HUMANS; MALEIMIDES; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 77953715126     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.04.015     Document Type: Article

References (38)

1. Aida S., Takatsuji M.O., Aotsuka S., Shimoji K., Yokohari R. Calcitonin inhibits production of immunoglobulins, rheumatoid factor and interleukin-1 by mononuclear cells from patients with rheumatoid arthritis. Ann. Rheum. Dis. 1994, 53:247-249.
2. Bauer H.H., Aebi U., Häner M., Hermann R., Müller M., Arvinte T., Merkle H.P. Architecture and polymorphism of fibrillar supramolecular assemblies produced by in vitro aggregation of human calcitonin. J. Struct. Biol. 1995, 115:1-15.
3. Cenni E., Granchi D., Avnet S., Fotia C., Salerno M., Micieli D., Sarpietro M.G., Pignatello R., Castelli F., Baldini N. Biocompatibility of poly(d-l-lactide-coglycolide) nanoparticles conjugated with aldenronate. Biomaterials 2008, 29:1400-1411.
4. Chambers T.J., Magnus C.J. Calcitonin alters behavior of isolated osteoclasts. J. Pathol. 1982, 136:27-39.
5. Chambers T.J. Calcitonin alters behaviour of isolated osteoclasts. J. Pathol. 1982, 136:97-106.
6. Chausmer A., Stuart C., Stevens M. Identification of testicular cell plasma membrane receptors for calcitonin. J. Lab. Clin. Med. 1980, 96:933-938.
7. Cheng W., Satyanarayanajois S., Lim L.Y. Aqueous-soluble, non-reversible lipid conjugate of salmon calcitonin: synthesis, characterization and in vivo activity. Pharm. Res. 2007, 24:99-110.
8. Cholewinski M., Lückel B., Horn H. Degradation pathways, analytical characterization and formulation strategies of a peptide and a protein calcitonin and human growth hormone in comparison. Pharm. Acta Helv. 1996, 71:405-419.
9. Doschak M.R., Kucharski C.M., Wright J.E.I., Zernicke R.F., Uludag H. Improved bone delivery of osteoprotegerin by bisphosphonate conjugation in a rat model of osteoarthritis. Mol. Pharm. 2009, 6:634-640.
10. D'Santos C.S., Nicholson G.C., Moseley J.M., Evans T., Martin T.J., Kemp B.E. Biologically active, derivatizable salmon calcitonin analog: design, synthesis and applications. Endocrinology 1988, 123:1483-1488.
11. Farley J., Dimai H.P., Stilt-Coffing B., Farley P., Pham T., Mohan S. Calcitonin increases the concentration of insulin-like growth factors in serum-free cultures of human osteoblast-line cells. Calcif. Tissue Int. 2000, 67:247-254.
12. Fouchereau-Peron M., Moukhtar M.S., Benson A.A., Milhaud G. Characterization of specific receptors for calcitonin in porcine lung. Proc. Natl. Acad. Sci. U.S.A. 1981, 78:3973-3975.
13. Fujisaki J., Tokunaga Y., Takahashi T., Kimura S., Shimojo F., Hata T. Osteotropic drug delivery system (ODDS) based on bisphosphonic prodrug. V. Biological disposition and targeting characteristics of osteotropic estradiol. Biol. Pharm. Bull. 1997, 20:1183-1187.
14. Gittens S.A., Matyas J.R., Zernicke R.F., Uludaĝ H. Imparting bone affinity to glycoproteins through the conjugation of bisphosphonates. Pharm. Res. 2003, 20:978-987.
15. Goltzman D. Interaction of calcitonin and calcitonin gene-related peptide at receptor sites in target tissues. Science (Washington, DC) 1985, 227:1343-1345.
16. Gorn A.H., Lin H.Y., Yamin M., Auron P.E., Flannery M.R., Tapp D.R., Manning C.A., Lodish H.F., Krane S.M., Goldring S.R. Cloning, characterization and expression of a human calcitonin receptor from an ovarian carcinoma cell line. J. Clin. Invest. 1992, 90:1726-1735.
17. Heymsfield S., Lohman T., Wang Z.M., Going S. Human Body Composition 2005, Human Kinetics. 2nd edition.
18. Hirabayashi H., Fujisaki J. Bone-specific drug delivery systems: approaches via chemical modification of bone-seeking agents. Clin. Pharmacokinet. 2003, 42:1319-1330.
19. Karsdal M.A., Sondergaard B.C., Arnold M., Christiansen C. Calcitonin affects both bone and cartilage: a dual action treatment for osteoarthritis. Ann. NY Acad. Sci. 2007, 1117:181-195.
20. Kasugai S., Fujisawa R., Waki Y., Miyamoto K., Ohya K. Selective drug delivery system to bone: small peptide (Asp)6 conjugation. J. Bone Miner. Res. 2000, 15:936-943.
21. Lee Y.H., Sinko P.J. Oral delivery of salmon calcitonin. Adv. Drug Deliv. Rev. 2000, 42:225-238.
22. Lee K.C., Park M.O., Na D.H., Youn Y.S., Lee S.D., Yoo S.D., Lee H.S., DeLuca P.P. Intranasal delivery of PEGylated salmon calcitonins: hypocalcemic effects in rats. Calcif. Tissue Int. 2003, 73:545-549.
23. Naot D., Cornish J. The role of peptides and receptors of the calcitonin family in the regulation of bone metabolism. Bone 2008, 43:813-818.
24. Nicholson G.C., D'Santos C.S., Evans T., Moseley J.M., Kemp B.E., Michelangeli V.P., Martin T.J. Human placental calcitonin receptors. Biochem. J. 1988, 250:877-882.
25. Okubo Y., Bessho K., Fujimura K., Kusumoto K., Ogawa Y., Iizuka T. Effect of e-calcitonin on oeteoinduction by recombinant human bone morphogenetic perotein-2. Biochem. Biophys. Res. Commun. 2000, 269:317-321.
26. Orme M.W., Labroo V.M. Synthesis of h-estradiol-3-benzoate-17-(succinyl-12a-tetracycline): a potential bone-seeking estrogen. Bioorg. Med. Chem. Lett. 1994, 4:1375-1380.
27. Pierce W.M., Waite L.C. Bone-targeted carbonic anhydrase inhibitors: effect of a proinhibitor on bone resorption in vitro. Proc. Soc. Exp. Biol. Med. 1987, 186:96-102.
28. Raisz L.G. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J. Clin. Invest. 2005, 115:3318-3325.
29. Rittel W., Maier R., Brugger B., Kamber B., Rimker B., Sieber P. Structure-activity relationship of human calcitonin. III. Biological activity of synthetic analogs with shortened or terminally modified peptide chains. Experientia 1976, 32:246-248.
30. Rogers M.J., Frith J.C., Luckman S.P., Coxon F.P., Benford H.L., Monkkonen J., Auriola S., Chilton K.M., Russell R.G.G. Molecular mechanisms of action of bisphosphonates. Bone 1999, 24:73S-79S.
31. Shin B.S., Jung J.H., Lee K.C., Yoo S.D. Nasal absorption and pharmacokinetic disposition of salmon calcitonin modified with low molecular weight polyethylene glycol. Chem. Pharm. Bull. 2004, 52:957-960.
32. Silvestroni L., Menditto A., Frajese G., Gnessi L. Identification of calcitonin receptors in human spermatozoa. J. Clin. Endocrinol. Metab. 1987, 65:742-746.
33. Torres-Lugo M., Peppas N.A. Transmucosal delivery systems for calcitonin: a review. Biomaterials 2000, 21:1191-1196.
34. Uludag H., Kousinioris N., Gao T., Kantoci D. Bisphosphonate conjugation to proteins as a means to impart bone affinity. Biotechnol. Prog. 2000, 16:258-267.
35. Uludag H., Gao T., Wohl G.R., Kantoci D., Zernicke R.F. Bone affinity of a bisphosphonate conjugated protein in vivo. Biotechnol. Prog. 2000, 16:1115-1118.
36. Warshawsky H., Goltzman D., Rouleau M.F., Bergeron J.J.M. Direct in vivo demonstration by radioautography of specific binding sites for calcitonin in skeletal and renal tissues of the rat. J. Cell Biol. 1980, 85:682-694.
37. Yokogawa K., Miya K., Sekido T., Higashi Y., Nomura M., Fujisawa R., Morito K., Masamune Y., Waki Y., Kasugai S., Miyamoto K.-i. Selective delivery of estradiol to bone by aspartic acid oligopeptide and its effects on ovariectomized mice. Endocrinology 2001, 142:1228-1233.
38. Youn Y.S., Jung J.Y., Oh S.H., Yoo S.D., Lee K.C. Improved intestinal delivery of salmon calcitonin by Lys18-amine specific PEGylation, stability, permeability, pharmacokinetic behavior and in vivo hypocalcemic efficacy. J. Control. Release 2006, 114:334-342.